FMC Chips Away at Its Balance Sheet While Waiting on Regulators

FMC cleared KOBAN in the UK, filed rimisoxafen in Brazil and won India antitrust approval for its $252 million unit sale, but shares sit near a 52-week low.

Two regulatory filings landed on September 28, and neither moved the needle for FMC Corporation. In the UK, the Chemicals Regulation Division cleared the herbicide KOBAN, whose active ingredient is pethoxamid, for use on rapeseed across Great Britain and Northern Ireland. On the same day, the Philadelphia-based crop chemicals maker submitted its registration dossier for the herbicide rimisoxafen to Brazilian authorities. The Brazilian filing covers a target market of more than 70 million hectares of soybean and corn, and marks the second global submission for the dual-mode-of-action molecule, following a US EPA filing in July 2026. FMC was quick to note that rimisoxafen is not yet registered in Brazil or anywhere else, and commercial sales remain a distant prospect.

That gap between regulatory milestones and actual revenue sits at the heart of FMC's predicament. Weaker demand, persistent pricing pressure and stiff competition have weighed on the company, a backdrop already visible in its second-quarter results released on July 29. Approvals and dossiers make for encouraging press releases, but they do not fill the coffers.

Divestment Clears a Key Hurdle

Further along the balance-sheet repair effort, FMC won clearance from India's competition regulator on September 29 for the full sale of subsidiary FMC India Private Limited to Crystal Crop Protection Limited. The seller is FMC Netherlands Holdings II B.V. together with affiliated entities, in a transaction previously announced at $252 million. India has long been treated as an indispensable growth engine for the global crop protection industry, so an established player's exit from its local operations rarely reflects strategic leisure. It is, rather, a push to unlock liquidity quickly and shore up the balance sheet.

The urgency is not hard to trace. Roughly two weeks ago, FMC completed an investment by Belgium's Tessenderlo Group, which took a stake of about 20.0 percent of share capital, along with the right to nominate an independent board member. Tessenderlo paid $13.30 per share, investing around $403 million for more than 30.3 million shares. The market barely blinked. Since that capital injection, the stock has shed 13.8 percent. A similar pattern played out on the technology front: about three weeks ago, FMC moved two RNA-based bioinsecticides into field development with AgroSpheres, a program spanning acreage in the US, Brazil and Asia. The shares have lost 15.6 percent since.

A Stock Pricing in Doubt

The equity has taken the strain without flinching. On Friday, the stock closed at EUR 7.50 in German trading, having earlier touched a fresh 52-week low of EUR 7.43. That leaves the shares just 1.0 percent above that trough and down 72 percent over the year.

Selling off the family silver buys near-term breathing room at the cash register, but it also shrinks the operating earnings base for years to come. Investors typically want more than emergency measures; they want a credible path to profitable growth once the cuts are done. On that front, the pipeline carries the burden of expectation, yet agrochemical timelines are unforgiving. Years can pass between a dossier submission and the first meaningful field revenue, and hopes for future blockbusters do little to ease present earnings weakness while approvals grind on.

October 29 Looms Large

The next real test arrives at the end of October. FMC has scheduled its third-quarter 2026 results for October 29 after the US market close, with management hosting a conference call the following day. Until those hard numbers land, there is little in the way of a compelling case for stepping in. Anyone betting on a turnaround would do better to wait for actual earnings rather than pin hopes on molecules still sitting on regulators' desks. FMC remains stuck in a classic restructuring phase: shrinking the balance sheet through asset sales and dilution from new shareholders buys time, but not yet a change in direction. The decisive question will be settled not in approval offices, but in the company's order books and financial statements.